ArticleEuropean journal of nuclear medicine and molecular imaging2018
Delayed response after repeated
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Pooled it
- Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.Medicine · 2020Pooled it
- Trial
- Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [Theranostics · 2025Article
- Quantification of biochemical PSA dynamics after radioligand therapy with [EJNMMI physics · 2024Article
- Design, Synthesis, and Biological Evaluation of a Novel [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Early biochemical and radiographic response after one cycle of [European journal of nuclear medicine and molecular imaging · 2023Article
- Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.Journal for immunotherapy of cancer · 2023Article
- Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.Frontiers in medicine · 2023Article
- Single Center Experience with a 4-WeekCancers · 2022Article
- 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.The oncologist · 2022Review
- mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.European journal of nuclear medicine and molecular imaging · 2022Article
- Review
- Hematological Toxicity in Mice after High Activity Injections ofPharmaceutics · 2022Article
- A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.Theranostics · 2022Article
- The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [European journal of nuclear medicine and molecular imaging · 2021Article
- Factors predicting biochemical response and survival benefits following radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated patients with metastatic castration resistant prostate cancer. The aim of this retrospective study was to analyze response in patients receiving 3 cycles of Lu-PSMA.
methodsSeventy-one patients (median age: 72 years; range 44-87) received 3 cycles of RLT with Lu-PSMA (mean administered activity: 6.016 ± 0.543 GBq) every 8 weeks. Response was evaluated using serum PSA levels and a PSA decline ≥50% was considered as biochemical response. Additionally, any PSA decline after the first cycle was evaluated for further therapy effects after the second and third cycle.
resultsA total of 213 cycles were performed in 71 patients. Data for response and adverse events were available for all patients. A PSA decline ≥50% and some PSA decline occurred in 56% and 66% of the patients. Of 30 patients with a PSA response after the first cycle, 28 remained responders and 12/41 of non-responders responded to further therapy cycles.
conclusionRLT with Lu-177-PSMA-617 shows respectable response rates. In this retrospective analysis, a relevant number of patients showed a delayed response, even if they did not respond to the first cycle of the therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.